The company acquired telehealth provider Sequence, which prescribes weight-loss drugs, for $106 million.
is unlikely to abate anytime soon, WeightWatchers announced that it has agreed to acquire Sequence, a weight-loss management telehealth company that touts its prescriptions for Ozempic and other similar GLP-1 agonist drugs, as they’re known medically, for $106 million.
Given the size of the potential market — the CDC estimates that over 70 percent of adult Americans are obese or overweight — Sequence’s success is perhaps unsurprising. And while WeightWatchers stresses the need for behavioral changes and nutrition programs it has always emphasized, its acquisition of Sequence suggests a bullish belief in the power of adding a pharmacological component as well, and in aannouncing the acquisition, the company’s chief scientific officer, Dr. Gary Foster, Ph.D.
The growing interest in Ozempic and similar drugs has put pressure on supplies and availability, leaving diabetics scrambling to fill their own prescriptions in the face of skyrocketing demand. “Don’t even bother calling,” one woman told me of her schlep from pharmacy to pharmacy looking for her medication.
Whether or not current patients are excited, investors are. WeightWatchers’ stock is up 79 percent today.
Australia Latest News, Australia Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
WeightWatchers is acquiring Sequence for $106 millionWeightWatchers is buying a company that lets you pay $99 a month to see a doctor on video and get a prescription to popular weight-loss drug Ozempic
Read more »
WeightWatchers to buy Sequence telehealth, enter obesity drug prescription businessWW International Inc, known as WeightWatchers, said on Monday it is acquiring subscription telehealth platform Sequence, moving the weight-loss program operator into the obesity drug prescription business. WeighWatchers said it expects its $132 million acquisition in cash and stock will complement its nutrition and behavior-change program for weight loss at a time when obesity drugs are seen as one of the biggest markets for drugmakers.
Read more »
WeightWatchers buys telehealth platform Sequence, facilitating access to Ozempic and WegovyThe diet company is hoping to offer members the ability to meet with clinicians who can prescribe obesity and diabetes medications.
Read more »
WeightWatchers Moves Into the Ozempic Market With Telehealth DealThe weight-management company is buying digital health company Sequence, which offers telehealth visits with doctors.
Read more »
WeightWatchers Bets on So-Called Miracle Obesity Drug Ozempic in New Deal: ReportThe Wall Street Journal reported Monday that WeightWatchers is buying a telehealth subscription service called Sequence, which allows doctors to prescribe both Ozempic and its sister drug, Wegovy.
Read more »
WSJ News Exclusive | WeightWatchers Moves Into the Ozempic Market With Telehealth DealThe weight-management company is buying digital health company Sequence, which offers telehealth visits with doctors.
Read more »